Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

A review of Controlled Drug incidents reported to the NRLS over seven years

By David Cousins, David Gerrett and Bruce Warner

Abstract

Aim

To describe the number and types of patient safety incidents involving Controlled Drugs reported to the National Reporting and Learning System (NRLS) and the role of Accountable Officers for CDs (AOs) in incident reporting and learning.

Design and setting

All medication safety incidents concerning CDs reported from the NHS in England and Wales occurring in the seven years from 1 January 2005 to 31 December 2011 were extracted from the NRLS and subject to quantitative inspection. In addition incidents with reported outcomes of death and severe harm were also analysed qualitatively.

Results

There were 72,028 in incidents reported to the NRLS over seven years. Of 10,678 incidents of reported harm, there were 54 deaths, 74 severe harms and 10,550 incidents of other harms. The risk of death with CD incidents was found to be significantly greater than with medication incidents generally (odds ratio 1.484, 95% CI 1.015–2.169). Incidents involving overdose of CDs accounted for 89 (69.5%) of the 128 incidents reporting of serious harm (death and severe harm). Five CDs (morphine, diamorphine, fentanyl, midazolam and oxycodone) were responsible for 113 incidents (88.4%) leading to serious harm. A detailed review of the 128 incident reports associated with serious harm found that only once incident had been referred to the AO.

Conclusion

Unsafe use of CDs is the number one cause of serious harm from medication incidents reported to the NRLS; in our view, better implementation of NPSA guidance could have prevented most of these incidents from harming patients. The role of the AO should prioritise reporting and learning of incidents that have caused serious harm.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2013.11125507

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary information

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.